[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
November 17, 2015

The Pendulum of Prostate Cancer Screening

Author Affiliations
  • 1Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee
  • 2VA Tennessee Valley Geriatric Research, Education, and Clinical Center, Nashville, Tennessee
JAMA. 2015;314(19):2031-2033. doi:10.1001/jama.2015.13775

In May 2012, the US Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA)–based screening for prostate cancer, giving it a grade D and concluding, “there is moderate certainty that the benefits of PSA-based screening from prostate cancer do not outweigh the harms.”1 Rather than put an end to this controversy over screening, this recommendation further fueled a contentious ongoing debate.

First Page Preview View Large
First page PDF preview
First page PDF preview
×